These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

324 related articles for article (PubMed ID: 21375467)

  • 1. Genotoxicity of retroviral hematopoietic stem cell gene therapy.
    Trobridge GD
    Expert Opin Biol Ther; 2011 May; 11(5):581-93. PubMed ID: 21375467
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Stem cell gene therapy: the risks of insertional mutagenesis and approaches to minimize genotoxicity.
    Wu C; Dunbar CE
    Front Med; 2011 Dec; 5(4):356-71. PubMed ID: 22198747
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gene therapy for inherited immunodeficiency.
    Touzot F; Hacein-Bey-Abina S; Fischer A; Cavazzana M
    Expert Opin Biol Ther; 2014 Jun; 14(6):789-98. PubMed ID: 24823313
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gene therapy for PIDs: progress, pitfalls and prospects.
    Mukherjee S; Thrasher AJ
    Gene; 2013 Aug; 525(2):174-81. PubMed ID: 23566838
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Parachuting in the epigenome: the biology of gene vector insertion profiles in the context of clinical trials.
    Baum C
    EMBO Mol Med; 2011 Feb; 3(2):75-7. PubMed ID: 21254403
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ten years of gene therapy for primary immune deficiencies.
    Aiuti A; Roncarolo MG
    Hematology Am Soc Hematol Educ Program; 2009; ():682-9. PubMed ID: 20008254
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dynamics of gene-modified progenitor cells analyzed by tracking retroviral integration sites in a human SCID-X1 gene therapy trial.
    Wang GP; Berry CC; Malani N; Leboulch P; Fischer A; Hacein-Bey-Abina S; Cavazzana-Calvo M; Bushman FD
    Blood; 2010 Jun; 115(22):4356-66. PubMed ID: 20228274
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gene therapy for severe combined immunodeficiencies and beyond.
    Fischer A; Hacein-Bey-Abina S
    J Exp Med; 2020 Jan; 217(2):. PubMed ID: 31826240
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gene therapy of primary T cell immunodeficiencies.
    Fischer A; Hacein-Bey-Abina S; Cavazzana-Calvo M
    Gene; 2013 Aug; 525(2):170-3. PubMed ID: 23583799
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gene Therapy for X-Linked Severe Combined Immunodeficiency: Where Do We Stand?
    Cavazzana M; Six E; Lagresle-Peyrou C; André-Schmutz I; Hacein-Bey-Abina S
    Hum Gene Ther; 2016 Feb; 27(2):108-16. PubMed ID: 26790362
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Murine leukemias with retroviral insertions at Lmo2 are predictive of the leukemias induced in SCID-X1 patients following retroviral gene therapy.
    Davé UP; Akagi K; Tripathi R; Cleveland SM; Thompson MA; Yi M; Stephens R; Downing JR; Jenkins NA; Copeland NG
    PLoS Genet; 2009 May; 5(5):e1000491. PubMed ID: 19461887
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Twenty-Five Years of Gene Therapy for ADA-SCID: From Bubble Babies to an Approved Drug.
    Ferrua F; Aiuti A
    Hum Gene Ther; 2017 Nov; 28(11):972-981. PubMed ID: 28847159
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A possible turning point in the hematopoietic stem cell gene therapy for primary immunodeficiency diseases? Lentiviral vectors could take the place of retroviral vectors.
    Ariga T
    Expert Rev Clin Immunol; 2013 Nov; 9(11):1015-8. PubMed ID: 24168409
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Retrovirus-induced oncogenesis and safety of retroviral vectors.
    Nair V
    Curr Opin Mol Ther; 2008 Oct; 10(5):431-8. PubMed ID: 18830918
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gene therapy for severe combined immunodeficiency caused by adenosine deaminase deficiency: improved retroviral vectors for clinical trials.
    Onodera M; Nelson DM; Sakiyama Y; Candotti F; Blaese RM
    Acta Haematol; 1999; 101(2):89-96. PubMed ID: 10202239
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gene Therapies for Primary Immune Deficiencies.
    Kohn LA; Kohn DB
    Front Immunol; 2021; 12():648951. PubMed ID: 33717203
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gene Therapy Approaches to Immunodeficiency.
    Ghosh S; Gaspar HB
    Hematol Oncol Clin North Am; 2017 Oct; 31(5):823-834. PubMed ID: 28895850
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lymphomagenesis in SCID-X1 mice following lentivirus-mediated phenotype correction independent of insertional mutagenesis and gammac overexpression.
    Ginn SL; Liao SH; Dane AP; Hu M; Hyman J; Finnie JW; Zheng M; Cavazzana-Calvo M; Alexander SI; Thrasher AJ; Alexander IE
    Mol Ther; 2010 May; 18(5):965-76. PubMed ID: 20354504
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sola dosis facit venenum. Leukemia in gene therapy trials: a question of vectors, inserts and dosage?
    Staal FJ; Pike-Overzet K; Ng YY; van Dongen JJ
    Leukemia; 2008 Oct; 22(10):1849-52. PubMed ID: 18769449
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genotoxicity assay for gene therapy vectors in tumor prone Cdkn2a⁻/⁻ mice.
    Montini E; Cesana D
    Methods Enzymol; 2012; 507():171-85. PubMed ID: 22365774
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.